

Edgar Filing: BIOGENTECH CORP - Form NT 10-Q

BIOGENTECH CORP  
Form NT 10-Q  
August 14, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12b-25  
NOTIFICATION OF LATE FILING

SEC File # :  
000-49620

(Check One): ( ) Form 10-K ( ) Form 20-F ( ) Form 11-K (X) Form 10-Q ( ) Form N-SAR

For Period Ended: June 30, 2003  
-----

- [ ] Transition Report on Form 10-K
- [ ] Transition Report on Form 20-F
- [ ] Transition Report on Form 11-K
- [ ] Transition Report on Form 10-Q
- [ ] Transition Report on Form N-SAR

For the Transition Period Ended: \_\_\_\_\_

-----  
Read Instruction (on back page) Before Preparing Form. Please Print or Type.  
Nothing in this form shall be construed to imply that the Commissions has  
verified any information contained herein.

-----  
If the notification relates to a portion of the filing checked above, identify  
the item(s) to which the notification relates:  
-----

PART I - REGISTRANT INFORMATION

-----  
Full Name of Registrant:  
Biogentech Corporation

-----  
Former Name if Applicable:  
Togs for Tykes, Inc.

-----  
Address of Principal Executive Office (Street and Number)  
2445 McCabe Way, Suite 150

-----  
City, State and Zip Code  
Irvine California, 92614  
-----

Edgar Filing: BIOGENTECH CORP - Form NT 10-Q

PART II - Rules 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box, if appropriate)

- (X)
  - (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
  - (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
  - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach Extra Sheets if Needed).

The Registrant hereby represents that it is unable to file its Quarterly Report on Form 10-QSB for the period ended June 30, 2003 without unreasonable effort or expense. The Company's auditor was not able to complete the review of Company's financial statements within the necessary period of time. The Registrant further represents that the Form 10-QSB will be filed by no later than August 20, 2003, which is the 5th day following the date on which the Form 10-QSB was due.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification.

Karin C. Carter	(408)	432-3043
(Name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities and Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

(X) Yes            ( ) No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ( ) Yes (X) No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons

Edgar Filing: BIOGENTECH CORP - Form NT 10-Q

why a reasonable estimate of the results cannot be made.

Biogentech Corporation, a Nevada corporation, has caused this notification to be signed on its behalf by the undersigned, thereunto duly authorized.

August 14, 2003

Biogentech Corporation  
a Nevada corporation

By: /s/ Chaslav Radovich

-----  
Chaslav Radovich

Its: President

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

-----  
ATTENTION:

Intentional misstatements or omissions of fact constitute Federal Criminal  
Violations (See 18 U.S.C. 1001).  
-----